Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Idiopathic Membranous Nephropathy
NCT00425217Phase 3Completed
- Sponsor
- Mayo Clinic
- Start
- Aug 2004
- Primary completion
- Apr 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in idiopathic membranous nephropathy (IMN), sponsored by Mayo Clinic. Started Aug 2004; status: completed.
02
Drugs
rituximab
03
Conditions
idiopathic membranous nephropathy (IMN)
Beyond the preview
Go deeper on NCT00425217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00425217.